Search Results - Clinical+Specialty+%3e+Oncology

26 Results Sort By:
TMEPAI for Diagnosis and Treatment of Breast Cancer
UT Health San Antonio researchers have developed an assay that detects overexpression of TMEPAI, a potential biomarker for aggressive cancer growth and invasion in TNBC patients. Dr. Saikumar’s team has identified compounds that inhibit the expression of TMEPAI and thus may represent therapeutic candidates to inhibit cancer proliferation and...
Published: 3/26/2021   |   Inventor(s): Pothana Saikumar, Prajjal Singha
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Clinical Specialty > Women's Health, Diagnostics > Biomarkers, Therapeutics > Small Molecule
Pharmacological EZH2 inhibition enhances cancer cell sensitivity to genotoxic insults through suppressing DNA damage repair
HSC-1535 Pharmacological EZH2 inhibition enhances cancer cell sensitivity to genotoxic insults through suppressing DNA damage repairKexin Xu: Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.Myles Brown: Center for Functional Cancer Epigenetics and Department of Medical Oncology,...
Published: 6/16/2020   |   Inventor(s): Kexin Xu, Myles Brown, Chen-Hao Chen, Xiaole Shirley Liu
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Clinical Specialty > Radiology, Diagnostics > Assay, Life Sciences Research Tools > Biomarkers
Discovery of a METTL3 inhibitor
METTL3 Inhibitors as Leukemia therapeuticsTHE PROBLEM Acute Myeloid LeukemiaAcute myeloid leukemia (AML) is a relatively rare cancer (1% of all cancer incidence cases), however it accounts for a disproportionally high number of cancer-related deaths. AML’s lethality can be contributed to its fast progression, low survivability, and high rate of...
Published: 5/7/2020   |   Inventor(s): Yogesh Gupta
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Therapeutics > Small Molecule
CsA treatment for BRCA1 mutant cancers
I have demonstrated that BRCA1-mutant triple-negative breast cancer (TNBC) cells are highly sensitive to cyclosporine (CsA) and non-immunosuppressive CsA-derivatives (NIM811 or Alisporivir). To determine whether CsA would also be effective in treating BRCA1-mutant TNBC cells in vivo, I set up a pilot study using a preclinical xenograft model to investigate...
Published: 2/14/2020   |   Inventor(s): Kimi Yuk-Ling Kong
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Clinical Specialty > Women's Health, Clinical Specialty > Endocrinology, Life Sciences Research Tools > Drug Screening, Therapeutics > Small Molecule
A new approach for treatment of liver cancers
The early stage of hepatocellular carinoma (HCC) tumors (<5cm) can either be excised surgically, or removed byablation therapy, but treatment of advanced stage HCC remain challegning. Since, HCC and other liver cancersare diagnosed at advanced stage, their surgical excision is not feasible. The existing front- and second-linetherapies for advanced...
Published: 2/14/2020   |   Inventor(s): Yogesh Gupta
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Life Sciences Research Tools > Drug Screening, Therapeutics > Small Molecule, Clinical Specialty > Hepatology
Novel Emulsion microspheres for Liver Tumors
In the last 15 years there has been a significant interest in administration of radiotherapeutic microspheres for treatment of liver tumors to deliver radiation to the liver tumors with beta particle radiation from yttrium-90.7 There has also been a recent interest in the development of biodegradable microspheres. In addition to microspheres, lipiodol,...
Published: 2/7/2020   |   Inventor(s): Ryan Bitar, William Phillips
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Medical Devices > Drug Delivery, Life Sciences Research Tools > Lipidomics, Medical Devices > Imaging, Therapeutics > Nanoparticles, Other > Nanotechnology
PARP1 and MGMT protein interaction in response to DNA damage induction
The invention is related to the protein interaction between PARP1 and MGMT that has not been shown before. These proteins belong to two DNA repair pathways: PARP1 repairs DNA damage as part of base excision repair mechanism, and MGMT is suicide protein repairing a single type of DNA lesion, O6-methylguanine. In untreated Ewing sarcoma cells, the levels...
Published: 2/7/2020   |   Inventor(s): Raushan Kurmasheva
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Therapeutics > Small Molecule
Small-molecule inhibitors of Nucleotide Excision Repair
Small molecule inhibitors of Nucleotide Excision RepairXPF/ERCC1 is a structure-specific nuclease whose activity is essential for nucleotide excision repair (NER),interstrand crosslink repair (ICL) and other pathways of DNA damage repair. In NER, the recruitment andactivation of XPF/ERCC1 depend on the interaction with XPA, another essential component...
Published: 2/7/2020   |   Inventor(s): Dmitri Ivanov
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Therapeutics > Small Molecule
MicroRNA mimics as potential differentiation agents for treating neuroblastoma
Neuroblastoma,themostcommonextracranialsolidtumorofchildhood,arisesfromneuralcrestcellprecursorsthatfailtodifferentiate.Inducingcelldifferentiationisanimportanttherapeuticstrategyforneuroblastoma.Wedevelopedadirectfunctionalhigh-­‐contentscreentoidentifydifferentiation-­‐inducingmicroRNAs,inordertodevelopmicroRNA-­‐baseddifferentiationtherapyforneuroblastoma.WediscoverednovelmicroRNAs,andmorestrikingly,threemicroRNAseedfamiliesthatinduceneuroblastomacelldifferentiation.Inaddition,weshowedthatmicroRNAseedfamilieswereoverrepresentedintheidentifiedgroupoffourteendifferentiation-­‐inducingmicroRNAs,suggestingthatmicroRNAseedfamiliesarefunctionallymoreimportantinneuroblastomadifferentiationthanmicroRNAswithuniquesequences.Wefurtherinvestigatedthedifferentiation-­‐inducingfunctionofthemicroRNA-­‐506-­‐3p/microRNA-­‐124-­‐3pseedfamily,whichwasthemostpotentinducerofdifferentiation.Weshowedthatthedifferentiation-­‐inducingfunctionofmicroRNA-­‐506-­‐3p/microRNA-­‐124-­‐3pismediated,atleastpartially,bydown-­‐regulatingexpressionoftheirtargetsCDK4andSTAT3.WefurthershowedthatexpressionofmiR-­‐506-­‐3p,butnotmiR-­‐124-­‐3p,isdramaticallyup...
Published: 12/13/2019   |   Inventor(s): Liqin Du, Alexander Pertsemlidis
Keywords(s):  
Category(s): Clinical Specialty > Oncology, Clinical Specialty > Neurology, Therapeutics > miRNA
Method of targeting liposomes to bone marrow
UT Health San Antonio and Waseda University in Shinjuku, Japan have collaboratively developed a drug delivery system capable of delivering a cargo preferentially to bone marrow. This drug delivery system shows promise for therapeutic and diagnostic applications for which the cells of the bone marrow play an important role. Background:Targeted anti-cancer...
Published: 10/16/2018   |   Inventor(s): William Phillips, Beth Goins, Keitaro Sou, Shinji Takeoka, Eishun Tsuchida
Keywords(s): Biologics, Drugs
Category(s): Clinical Specialty > Oncology, Therapeutics > Biologics, Therapeutics > Other
1 2 3